At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before.
Syndax is currently focused on the development of entinostat, an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body’s immune response to tumors. We are developing entinostat as a combination therapy in multiple cancer indications with our initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer.
Entinostat is currently being evaluated as a combination therapeutic in a Phase 1b/2 clinical trial with Merck & Co., Inc. in patients with non-small cell lung cancer and melanoma, and we plan to evaluate entinostat in Phase 1b/2 clinical trials with Genentech in patients with triple-negative breast cancer in the first half of 2016, and with Merck KGaA, Darmstadt, Germany and Pfizer in patients with ovarian cancer in the second half of 2016. We are also developing entinostat for use in advanced hormone receptor positive, or HR+, breast cancer. Following positive results from our Phase 2b clinical trial, ENCORE 301, entinostat, in combination with Aromasin® (exemestane tablets), was granted breakthrough therapy designation by the U.S. Food and Drug Administration in advanced HR+ breast cancer, an indication for which it is currently being evaluated in a Phase 3 clinical trial.
Syndax is headquartered in Waltham, Massachusetts.